重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响

doi:10.11904/j.issn.1002-3070.2016.06.010

摘要/Abstract

摘要： 目的探讨重组人血管内皮抑素联合长春瑞滨＋顺铂(NP)化疗对初诊晚期非小细胞肺癌骨转移患者的疗效和血清血管内皮生长因子的影响。方法于2009年1月—2012年1月间收治的初诊晚期非小细胞肺癌骨转移患者40例，随机分为治疗组(20例)和对照组(20例)，对照组予以单纯NP化疗，治疗组予以重组人血管内皮抑素联合NP化疗，比较两组的临床疗效和治疗前后血清血管内皮生长因子的变化。结果经过两周期全身化疗后，治疗组的客观缓解率和疾病控制率分别为30.0%和80.0%，对照组分别为5.0%和45.0%，治疗组的客观缓解率和疾病控制率均显著高于对照组(P＜0.05)。两组治疗前后血清血管内皮生长因子的变化无统计学意义(P＞0.05)。两组患者的不良反应发生率无统计学差异(P＞0.05)。结论重组人血管内皮抑素联合NP方案可提高初诊晚期非小细胞肺癌骨转移患者治疗效果，且不会增加不良反应的发生率，但是血清血管内皮生长因子变化不明显。

关键词: 非小细胞肺癌, 骨转移, 化疗, 重组人血管内皮抑素, 血管内皮生长因子

Abstract: Objective To explore the efficacy of recombinant human endostatin(Rh-endostatin)combined with vinorelbine-cisplatin(NP)regimen for newly diagnosed patients with advanced non-small cell lung cancer(NSCLC)with bone metastases and the impact on expression of serum vascular endothelial growth factor(VEGF).Methods From January 1,2009 to February 1,2012,a total of 40 with newly diagnosed,advanced NSCLC patients with bone metastases were enrolled in this study and randomly assigned to the treatment(N=20)or control(N=20)group.The control group was only given the NP regimen chemotherapy and the treatment group was treated with Rh-endostatin combined with NP regimen.The changes in clinical effects of the two groups and serum VEGF levels were observed.Results After two cycles of systemic chemotherapy,objective response rate(ORR)and disease control rate(DCR)of the treatment group were 30.0% and 80.0% significantly higher than 5.0% and 45.0% of the control group(P＜0.05).Serum VEGF Level did not significantly change before and after treatments in the two groups(P＞0.05).Conclusion Rh-endostatin combined with NP regimen can improve the efficiency of treatment for newly diagnosed patients with advanced NSCLC with bone metastases and does not increase adverse reactions whereas no significant difference in serum VEGF Levels.

Key words: Non-small cell lung cancer, Bone metastases, Chemotherapy, Recombinant human endostatin, Vascular endothelial growth factor

中图分类号:

R734.2

张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.

ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.

参考文献

1 Wang J,Wang K,Xu J,et al.Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients:a meta-analysis[J].PLoS One,2013,8(11):e78070.
2 Rossi A,Chiodini P,Sun JM,et al.Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer:a systematic review and meta-analysis of individual patient data[J].Lancet Oncol,2014,15(11):1254-1262.
3 Ge W,Cao DD,Wang HM,et al.Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs:a meta-analysis[J].Asian Pac J Cancer Prev,2011,12(10):2705-2711.
4 Sun JM,Ahn JS,Lee S,et al.Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases[J].Lung Cancer,2011,71(1):89-93.
5 Lopez-Olivo MA,Shah NA,Pratt G,et al.Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease:a systematic review and meta-analysis[J].Support Care Cancer,2012,20(11):2985-2998.
6 Costelloe CM,Chuang HH,Madewell JE,et al.Cancer response criteria and bone metastases:RECIST 1.1,MDA and PERCIST[J].J Cancer,2010,1(6):80-92.
7 Hosseini H,Rajabibazl M,Ebrahimizadeh W,et al.Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF[J].Microvasc Res,2015,97(1):13-18.
8 刘黎,毛英,张匠,等.重组人血管内皮抑制素注射液联合顺铂对非小细胞肺癌患者血管内皮生长因子的影响研究[J].实用心脑肺血管病杂志,2016,24(3):127-128.
9 Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186.
10 Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J].Science,2005,307(5706):58-62.
11 Herbst RS,Ansari R,Bustin F,et al.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy(BeTa):a double-blind,placebo-controlled,phase 3 trial[J].Lancet,2011,377(9780):1846-1854.
12 Niho S,Kunitoh H,Nokihara H,et al.Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer[J].Lung Cancer,2012,76(3):362-367.
13 Zhao X,Mei K,Cai X,et al.A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer[J].Invest New Drugs,2012,30(3):1144-1149.
14 Liu ZJ,Wang J,Wei XY,et al.Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer[J].J Cancer Res Clin Oncol,2012,138(6):927-937.
15 Sato Y.Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J].Cancer Sci,2011,102(7):1253-1256.
16 Han B,Xiu Q,Wang H,et al.A multicenter,randomized,double-blind,placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer[J].J Thorac Oncol,2011,6(6):1104-1109.
17 Yang F,Tang X,Riquelme E,et al.Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy[J].Cancer Res,2011,71(16):5512-5521.
18 Chen J,Yao Q,Li D,et al.Neoadjuvant rh-endostatin,docetaxel and epirubicin for breast cancer:efficacy and safety in a prospective,randomized,phase II study[J].BMC Cancer,2013,13(5):248-255.
19 Zhu Q,Zang Q,Jiang ZM,et al.Clinical application of Recombinant human endostatin in postoperative early complementary therapy on patients with Non-small cell lung cancer in Chinese Mainland[J].Asian Pac J Cancer Prev,2015,16(9):4013-4018.
20 Dahabreh IJ,Linardou H,Kosmidis P,et al.EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment:a systematic review and meta-analysis in non-small-cell lung cancer[J].Ann Oncol,2011,22(3):545-552.
21 Singh T,Kaur V,Kumar M,et al.The critical role of bisphosphonates to target bone cancer metastasis:an overview[J].J Drug Target,2015,23(1):1-15.
22 Brodowicz T,O′Byrne K,Manegold C.Bone matters in lung cancer[J].Ann Oncol,2012,23(9):2215-2222.
23 Song Z,Zhang Y.Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases[J].Med Oncol,2014,31(4):898.
24 Yuen T,Stachnik A,Iqbal J,et al.Bisphosphonates inactivate human EGFRs to exert antitumor actions[J].Proc Natl Acad Sci U S A,2014,111(50):17989-17994.

[1]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	梁虹, 李奇, 王耀先, 靳红, 王铜, 王亚楠, 段雅妮, 宋敏. 宫颈癌化疗心血管毒性预防的间断时间序列试验[J]. 实用肿瘤学杂志, 2019, 33(2): 134-138.
[4]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[5]	秦岚群, 邹征云. 恶性黑色素瘤化疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 167-172.
[6]	常晓霞综述, 宋冰冰, 刘家仁审校. 植物化学物增加肿瘤细胞对化疗药物敏感性的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 67-72.
[7]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[8]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[9]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[10]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[11]	张莉, 方可薇, 岳茜, 王红, 杨汉丰, 徐晓雪. 冷冻消融治疗骨转移瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 353-356.
[12]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[13]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[14]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[15]	孟志英, 于松涛, 张晶晶, 金惠敏. 宫颈癌下颌骨转移1例报告并文献复习[J]. 实用肿瘤学杂志, 2018, 32(2): 122-124.